UroGen Pharma Ltd. (LON:0XOD)
18.80
+0.30 (1.60%)
At close: Sep 5, 2025
UroGen Pharma Revenue
UroGen Pharma had revenue of $24.22M USD in the quarter ending June 30, 2025, with 10.83% growth. This brings the company's revenue in the last twelve months to $94.24M, up 10.85% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.
Revenue (ttm)
$94.24M
Revenue Growth
+10.85%
P/S Ratio
10.64
Revenue / Employee
$401.01K
Employees
235
Market Cap
731.77M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
HSBC Holdings | 41.03B |
Shell | 198.54B |
Unilever | 51.24B |
Rolls-Royce Holdings | 19.54B |
British American Tobacco p.l.c. | 25.60B |
Rio Tinto Group | 39.22B |
BP p.l.c. | 134.89B |